Records 1 - 4
| Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.
Oncotarget 2018 Mar 9 (18): 14109-14123.
Zhang Yuanyuan, Mai Haixing, Guo Gang, Bi Guofang, Hao Guangtao, Li Yuanyuan, Wang Xiaofang, Cheng Longmei, Wang Jing, Dong Ruihua, Liu Zeyuan, Chen Lijun, Qu Hengy
| PDGFRa promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 Oct 39 (10): 1010428317713857.
Guru Sameer Ahmad, Mir Rashid, Bhat Musadiq, Najar Imtiyaz, Zuberi Mariyam, Sumi Mamta, Masroor Mirza, Gupta Naresh, Saxena Alpa
| Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Cancer chemotherapy and pharmacology 2013 Oct 72 (4): 825-35.
Kim Hye Ryun, Park Hyung Soon, Kwon Woo Sun, Lee Ji Hyun, Tanigawara Yusuke, Lim Sun Min, Kim Hyo Song, Shin Sang Jun, Ahn Jung Bae, Rha Sun You
| Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Investigational new drugs 2012 Apr 30 (2): 819-27.
Yoon Dok Hyun, Ryu Min-Hee, Ryoo Baek-Yeol, Beck Moyeol, Choi Dae Ro, Cho Yoojin, Lee Jae-Lyun, Chang Heung-Moon, Kim Tae Won, Kang Yoon-K